<p>Vera Therapeutics, Inc. (NASDAQ:VERA - 獲取免費報告) 的股價在週五創下 52 周新高，此前美國銀行將該股的目標價從 48.00 美元上調至 66.00 美元。美國銀行目前對該股維持買入評級。Vera Therapeutics 的股價最高達到 51.72 美元，最後交易價為 51.2720 美元，成交量為 751409 股。該股此前收盤價為 47.69 美元。</p>
<p>獲取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
<p>其他幾位分析師也對該股發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Vera Therapeutics 股票的 “賣出（d-）” 評級。Cantor Fitzgerald 在 11 月 26 日的研究報告中重申了對 Vera Therapeutics 股票的 “增持” 評級。摩根大通將 Vera Therapeutics 的目標價從 99.00 美元下調至 96.00 美元，並在週五的報告中對該公司設定了 “增持” 評級。TD Cowen 在 12 月 5 日的報告中將 Vera Therapeutics 的目標價從 60.00 美元上調至 73.00 美元，並給予該公司 “買入” 評級。最後，Pivotal Research 在 12 月 5 日的報告中對 Vera Therapeutics 設定了 73.00 美元的價格目標。十位股票研究分析師對該股給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “適度買入”，共識目標價為 74.83 美元。</p>
<p><strong>查看我們關於 VERA 的最新研究報告</strong></p>
<h2>內部買賣情況</h2>
<p>在 Vera Therapeutics 的其他消息中，高級副總裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股 Vera Therapeutics 股票。該股票的平均售價為 29.06 美元，總交易額為 435,900.00 美元。出售後，該高級副總裁直接持有公司 47,839 股股票，價值 1,390,201.34 美元。此次交易使其持股減少了 23.87%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，董事 Patrick G. Enright 在 12 月 11 日的交易中購買了 5,882 股 Vera Therapeutics 股票。該股票的平均購買價格為每股 42.50 美元，總交易額為 249,985.00 美元。完成購買後，該董事直接持有公司 5,882 股股票，價值 249,985 美元。此次交易使其持股增加了∞。該購買的披露信息可在 SEC 文件中找到。公司內部人士持有公司股票的 16.30%。</p>
<h2>機構資金流入和流出</h2>
<p>最近幾家對沖基金買賣了 VERA 的股票。Bollard Group LLC 在第二季度以 1,509,000 美元的估值購買了 Vera Therapeutics 的新頭寸。Trexquant Investment LP 在第一季度將其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 現在擁有 62,777 股公司股票，價值 1,508,000 美元，此前在上個季度又購買了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度以約 326,000 美元的估值購買了 Vera Therapeutics 的新股份。Hudson Bay Capital Management LP 在第二季度以約 7,044,000 美元的估值收購了 Vera Therapeutics 的新股份。最後，American Century Companies Inc.在第二季度將其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.現在擁有 714,428 股公司股票，價值 16,832,000 美元，此前在該期間又購買了 336,978 股。99.21% 的股票由機構投資者和對沖基金持有。</p>
<h2>Vera Therapeutics 股票上漲 7.2%</h2>
<p>該公司的市值為 32.7 億美元，市盈率為-12.78，貝塔值為 1.21。該公司的流動比率為 12.21，速動比率為 12.21，債務與股本比率為 0.19。該公司的 50 日移動平均價格為 33.47 美元，200 日移動平均價格為 27.17 美元。</p>
<p>Vera Therapeutics (NASDAQ:VERA - 獲取免費報告) 最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為 (-1.26) 美元，低於市場共識預期的 (-1.20) 美元，差額為 (-0.06) 美元。在去年同期，該公司的每股收益為 (-0.85) 美元。賣方分析師預測 Vera Therapeutics, Inc.在本年度的每股收益將為-2.89 美元。</p>
<h2>Vera Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Vera Therapeutics 是一家臨牀階段的生物技術公司，專注於開發新型免疫療法，利用人體自身的調節性 T 細胞治療自身免疫和炎症性疾病。通過利用專有的蛋白質工程平台，該公司設計了選擇性針對 Treg 的細胞因子變體，旨在恢復免疫平衡並提供針對性的、具有疾病修正作用的效果。其產品管線包括多個針對慢性炎症和自身免疫特徵的臨牀前和臨牀候選藥物。</p>
<p>Vera Therapeutics 成立於 2018 年，總部位於馬薩諸塞州劍橋市，與領先的學術和研究機構合作，推動其開發項目。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
<li>製造業股票投資</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
<li>三隻天然氣股票提供優厚的分紅收益</li>
<li>META 在科技下滑中上漲，分析師稱特朗普的人工智能命令受到讚揚</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Vera Therapeutics 嗎？</h2>
<p>在考慮 Vera Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Vera Therapeutics 並不在名單上。</p>
<p>雖然 Vera Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VERA

<p>Vera Therapeutics（納斯達克代碼：VERA）在美國銀行將其目標價從 48 美元上調至 66 美元並維持買入評級後，達到了新的 52 周高點。該股最高交易價格為 51.72 美元，收盤價為 51.27 美元，較 47.69 美元上漲。分析師的評級各不相同，普遍目標價為 74.83 美元。內部交易和機構投資活躍，99.21% 的股份由機構持有。Vera Therapeutics 專注於開發針對自身免疫疾病的免疫療法</p>

<p>Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report)'s stock price hit a new 52-week high on Friday after Bank of America raised their price target on the stock from $48.00 to $66.00. Bank of America currently has a buy rating on the stock. Vera Therapeutics traded as high as $51.72 and last traded at $51.2720, with a volume of 751409 shares. The stock had previously closed at $47.69.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc. (NASDAQ:VERA - 獲取免費報告) 的股價在週五創下 52 周新高，此前美國銀行將該股的目標價從 48.00 美元上調至 66.00 美元。美國銀行目前對該股維持買入評級。Vera Therapeutics 的股價最高達到 51.72 美元，最後交易價為 51.2720 美元，成交量為 751409 股。該股此前收盤價為 47.69 美元。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
</div><p>Several other analysts have also commented on the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. JPMorgan Chase &amp; Co. lowered their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a report on Friday. TD Cowen boosted their target price on Vera Therapeutics from $60.00 to $73.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 5th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.83.</p>
<div class="lb-trans"><p>其他幾位分析師也對該股發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Vera Therapeutics 股票的 “賣出（d-）” 評級。Cantor Fitzgerald 在 11 月 26 日的研究報告中重申了對 Vera Therapeutics 股票的 “增持” 評級。摩根大通將 Vera Therapeutics 的目標價從 99.00 美元下調至 96.00 美元，並在週五的報告中對該公司設定了 “增持” 評級。TD Cowen 在 12 月 5 日的報告中將 Vera Therapeutics 的目標價從 60.00 美元上調至 73.00 美元，並給予該公司 “買入” 評級。最後，Pivotal Research 在 12 月 5 日的報告中對 Vera Therapeutics 設定了 73.00 美元的價格目標。十位股票研究分析師對該股給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “適度買入”，共識目標價為 74.83 美元。</p>
</div><p><strong>View Our Latest Research Report on VERA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 VERA 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. The trade was a 23.87% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of Vera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the purchase, the director directly owned 5,882 shares of the company's stock, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>在 Vera Therapeutics 的其他消息中，高級副總裁 Joseph R. Young 在 11 月 11 日的交易中出售了 15,000 股 Vera Therapeutics 股票。該股票的平均售價為 29.06 美元，總交易額為 435,900.00 美元。出售後，該高級副總裁直接持有公司 47,839 股股票，價值 1,390,201.34 美元。此次交易使其持股減少了 23.87%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，董事 Patrick G. Enright 在 12 月 11 日的交易中購買了 5,882 股 Vera Therapeutics 股票。該股票的平均購買價格為每股 42.50 美元，總交易額為 249,985.00 美元。完成購買後，該董事直接持有公司 5,882 股股票，價值 249,985 美元。此次交易使其持股增加了∞。該購買的披露信息可在 SEC 文件中找到。公司內部人士持有公司股票的 16.30%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of VERA. Bollard Group LLC bought a new position in Vera Therapeutics in the 2nd quarter valued at $1,509,000. Trexquant Investment LP boosted its holdings in Vera Therapeutics by 187.1% during the first quarter. Trexquant Investment LP now owns 62,777 shares of the company's stock worth $1,508,000 after buying an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Vera Therapeutics in the 1st quarter valued at about $326,000. Hudson Bay Capital Management LP acquired a new stake in shares of Vera Therapeutics in the 2nd quarter valued at approximately $7,044,000. Finally, American Century Companies Inc. grew its holdings in Vera Therapeutics by 89.3% during the second quarter. American Century Companies Inc. now owns 714,428 shares of the company's stock valued at $16,832,000 after purchasing an additional 336,978 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近幾家對沖基金買賣了 VERA 的股票。Bollard Group LLC 在第二季度以 1,509,000 美元的估值購買了 Vera Therapeutics 的新頭寸。Trexquant Investment LP 在第一季度將其在 Vera Therapeutics 的持股增加了 187.1%。Trexquant Investment LP 現在擁有 62,777 股公司股票，價值 1,508,000 美元，此前在上個季度又購買了 40,913 股。Dynamic Technology Lab Private Ltd 在第一季度以約 326,000 美元的估值購買了 Vera Therapeutics 的新股份。Hudson Bay Capital Management LP 在第二季度以約 7,044,000 美元的估值收購了 Vera Therapeutics 的新股份。最後，American Century Companies Inc.在第二季度將其在 Vera Therapeutics 的持股增加了 89.3%。American Century Companies Inc.現在擁有 714,428 股公司股票，價值 16,832,000 美元，此前在該期間又購買了 336,978 股。99.21% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Vera Therapeutics Stock Up 7.2%</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票上漲 7.2%</h2>
</div><p>The company has a market cap of $3.27 billion, a price-to-earnings ratio of -12.78 and a beta of 1.21. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The firm's fifty day moving average price is $33.47 and its 200-day moving average price is $27.17.</p>
<div class="lb-trans"><p>該公司的市值為 32.7 億美元，市盈率為-12.78，貝塔值為 1.21。該公司的流動比率為 12.21，速動比率為 12.21，債務與股本比率為 0.19。該公司的 50 日移動平均價格為 33.47 美元，200 日移動平均價格為 27.17 美元。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the prior year, the business earned ($0.85) earnings per share. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vera Therapeutics (NASDAQ:VERA - 獲取免費報告) 最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為 (-1.26) 美元，低於市場共識預期的 (-1.20) 美元，差額為 (-0.06) 美元。在去年同期，該公司的每股收益為 (-0.85) 美元。賣方分析師預測 Vera Therapeutics, Inc.在本年度的每股收益將為-2.89 美元。</p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家臨牀階段的生物技術公司，專注於開發新型免疫療法，利用人體自身的調節性 T 細胞治療自身免疫和炎症性疾病。通過利用專有的蛋白質工程平台，該公司設計了選擇性針對 Treg 的細胞因子變體，旨在恢復免疫平衡並提供針對性的、具有疾病修正作用的效果。其產品管線包括多個針對慢性炎症和自身免疫特徵的臨牀前和臨牀候選藥物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立於 2018 年，總部位於馬薩諸塞州劍橋市，與領先的學術和研究機構合作，推動其開發項目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Manufacturing Stocks Investing</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
<li>製造業股票投資</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
<li>三隻天然氣股票提供優厚的分紅收益</li>
<li>META 在科技下滑中上漲，分析師稱特朗普的人工智能命令受到讚揚</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Vera Therapeutics 嗎？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vera Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Vera Therapeutics 並不在名單上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vera Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Vera Therapeutics (NASDAQ:VERA) 在分析師上調評級後創下新的 12 個月高點